Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04860752
Other study ID # 2020-02
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 20, 2021
Est. completion date July 2024

Study information

Verified date June 2023
Source Edwards Lifesciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will evaluate real-world outcomes for the SAPIEN 3 Ultra Transcatheter Heart Valve System in transcatheter aortic valve implantation centres that are implementing minimalist periprocedural practices and facilitating early discharge home.


Description:

This is a prospective, observational, single-arm, multicentre, post-market study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 79 Years
Eligibility Inclusion Criteria: 1. Will undergo TAVI with the Edwards SAPIEN 3 Ultra System 2. Less than 80 years of age at time of the procedure 3. Low surgical risk 4. Meets clinical and procedural requirements for early discharge 5. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent Exclusion Criteria: 1. Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship 2. Considered to be part of a vulnerable population 3. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 4. Cannot tolerate an anticoagulation/antiplatelet regimen 5. Active bacterial endocarditis 6. Participating in a drug or device study that has not reached its primary endpoint

Study Design


Intervention

Device:
Transcatheter Aortic Valve Implantation (TAVI)
Subjects will undergo TAVI

Locations

Country Name City State
Austria LKH-Univ. Graz Klinik, Auenbruggerplaz 15 Graz
Austria Universitaetsklinikum St. Poelten, Klinik fuer Innere Medizin 3 St. Poelten
Austria Medizinische Universitaet Vienna Vienna
Finland Helsinki University Hospital Helsinki
Finland Tampere University Hospital, Teiskontie 35 Tampere
France Clinique St Augustin Bordeaux
France Institut Hospitalier Jacques Cartier Massy Massy
France CHU Bordeaux Hôpital Haut-Lévêque Pessac
France CHU Hopital Charles Nicolle Rouen Rouen
Germany Hdz Bad Oeynhausen Bad Oeynhausen
Germany Deutches Herzzentrum Berlin Berlin
Germany Universitäres Herz- und Gefäßzentrum UKE Hamburg Hamburg
Germany UKSH University Hospital Kiel Kiel
Germany Hospital Universitaet Mainz Mainz
Germany Deutsches Herzzentrum Muenchen Muenchen
Germany LMU, Klinikum der Universitaet Meunchen - Großhadern München
Italy Ospedale Moscati, Contrada Amoretta Avellino
Italy Azienda Ospedaliera Universitaria Federico II Napoli
Italy Irccs Ismett Palermo
Italy Ospedale San Camillo Roma
Italy Ospedale Santissima Annunziata Sassari
Italy Ospedale Mauriziano Torino
Italy Azienda ULSS2 Marca Trevigiana Treviso
Italy Ospedale Civile Maggiore Verona
Norway Oslo Universitetssykehus Rikshospitalet Oslo
Portugal Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental , Estrada do Forte do Alto do Duque Lisbon
Portugal Hospital Santa Maria Lisbon
Portugal Centro Hospitalar de Vila Nova de Gaia Vila Nova de Gaia
Spain Complexo Hospitalario Universitario Coruna Coruna
Spain Hospital Universitario Clínico San Carlos Madrid
Spain Hospital Clinico Universitario Virgen de la Arrixaca Murcia
Spain Hospital Universitario Valdecilla Santander, Av. de Valdecilla 25 Santander
Spain Hospital Alvara Cunqueiro, Estrada de Clara Campoamor 341 Vigo
Switzerland Universitatsspital Zurich Zürich
United Kingdom Leeds General Infirmary Leeds
United Kingdom St Thomas' Hospital London
United Kingdom Oxford John Radcliffe Hospital Oxford

Sponsors (1)

Lead Sponsor Collaborator
Edwards Lifesciences

Countries where clinical trial is conducted

Austria,  Finland,  France,  Germany,  Italy,  Norway,  Portugal,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of index hospitalization Number of days in hospital after the procedure Discharge, expected to be within 1-5 days post-procedure
See also
  Status Clinical Trial Phase
Completed NCT03186339 - Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Active, not recruiting NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease